Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer

 Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer

Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer

Shots:

  • The P-Ib/II study involves assessing of Onvansertib + Folfiri and bevacizumab in 44 patients with 2L treatment of KRAS-mutated mCRC. The company also provided an additional data update from its mCRC clinical program and initial findings from its EAP
  • Out of the 12 P-1b patients, 42% achieved PR & 67% have shown a durable response ranging from 6.1-13.7mos. The RP2D has been established at 15mg/m2 and the P-II segment of the ongoing trial is open to full enrollment of ~26 patients across 6 sites in the US
  • In the EAP, 66% of the initial 9 patients treated have shown tumor shrinkage and remain on treatment to-date with durable responses lasting an avg. of 6 mos.

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Cardiff oncology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post